Cosmo Bio USA lands exclusive U.S. deal for Bio-ReCell T-cell kits

Cosmo Bio USA has become the exclusive U.S. distributor of Bio-ReCell’s Atract T-Cell Activation Kits, giving American researchers broader access to tools used in CAR-T manufacturing, immunotherapy development and other cell therapy workflows. The partnership is aimed at reducing process variability and simplifying cell processing across multiple lab platforms.

Why it matters: - The deal gives U.S. researchers access to a T-cell activation system designed for reproducible results in cell therapy, translational research and regenerative medicine. - The Atract kit line is positioned for workflows where cleaner cell products, higher proliferation and scalable expansion can affect downstream research quality. - The partnership could make advanced cell processing tools easier to source in the United States.

What happened: - Cosmo Bio USA said June 22, 2026, that it entered an exclusive partnership to distribute Bio-ReCell’s Atract T-Cell Activation Kits in the United States. - The collaboration makes Cosmo Bio USA the exclusive U.S. distributor for the product line. - The announcement was made from Carlsbad, California.

The details: - Bio-ReCell’s flagship Atract T-Cell Activation Kit is built for robust and reproducible T-cell activation. - The kits are intended for CAR-T cell manufacturing, immunotherapy development and advanced cell culture workflows. - The system is designed to support high proliferation rates, strong activation efficiency and scalable expansion. - The kits are compatible with flasks, bags, plates and G-Rex systems. - Cosmo Bio USA said the partnership will expand U.S. researchers’ access to Bio-ReCell’s advanced cell processing technologies. - The company said the access will support cell therapy development, translational research and regenerative medicine. - Theresa Schaub, division president and chief operating officer of Cosmo Bio USA, said the partnership should give U.S. customers a simple solution that produces cleaner cell products, reduced process variability and streamlined workflows. - Luka Fajs, CEO of Bio-ReCell, said the company was founded to provide reliable alternatives that deliver cleaner, residue-free results while simplifying cell processing workflows. - Fajs said Bio-ReCell expects U.S. researchers to apply the kits in their work and drive new breakthroughs. - Cosmo Bio USA included a product link for more information: the company’s product page

Between the lines: - The exclusive-distribution model suggests Cosmo Bio USA is betting on specialized cell-processing tools as a growth area in U.S. life science research. - The emphasis on cleaner products, reduced variability and scalable expansion points to demand for workflows that are easier to standardize across different lab formats. - Bio-ReCell is using the partnership to reach a larger biotech market without building its own U.S. commercial channel.

What's next: - U.S. researchers can now access the Atract T-Cell Activation Kits through Cosmo Bio USA. - Bio-ReCell and Cosmo Bio USA are likely to lean on the partnership to expand adoption in cell and gene therapy research settings. - Further product uptake will depend on whether the kits perform as promised across lab and manufacturing platforms.